List of Excipients in Branded Drug FOSAPREPITANT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actavis Pharma Inc	FOSAPREPITANT	fosaprepitant	0591-4385	EDETATE DISODIUM
Actavis Pharma Inc	FOSAPREPITANT	fosaprepitant	0591-4385	HYDROCHLORIC ACID
Actavis Pharma Inc	FOSAPREPITANT	fosaprepitant	0591-4385	MEGLUMINE
Actavis Pharma Inc	FOSAPREPITANT	fosaprepitant	0591-4385	POVIDONE K12

Generic Drugs Containing FOSAPREPITANT

Company	Ingredient	NDC	Excipient
Baxter Healthcare Corporation	fosaprepitant dimeglumine	0338-0008	ANHYDROUS LACTOSE
Baxter Healthcare Corporation	fosaprepitant dimeglumine	0338-0008	EDETATE DISODIUM
Baxter Healthcare Corporation	fosaprepitant dimeglumine	0338-0008	HYDROCHLORIC ACID
Baxter Healthcare Corporation	fosaprepitant dimeglumine	0338-0008	POLYSORBATE 80

What are the Most Frequently-Used Excipients in FOSAPREPITANT?

# Of NDCs	Excipient
37	ANHYDROUS LACTOSE
37	EDETATE DISODIUM
4	EDETATE SODIUM
41	HYDROCHLORIC ACID

Fosaprepitant Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Fosaprepitant is an intravenous neurokinin-1 receptor antagonist prodrug used to prevent chemotherapy-induced nausea and vomiting. Its commercial value is concentrated in formulation execution rather than active-ingredient differentiation. The main opportunities are polysorbate-free delivery, ready-to-use presentations, lower-volume administration, improved compatibility, reduced hypersensitivity risk, and hospital procurement advantages.

The reference product, Emend for Injection, uses fosaprepitant dimeglumine with polysorbate 80 and lactose in a lyophilized formulation. Competing injectable aprepitant products use emulsion technology rather than the fosaprepitant prodrug. That distinction creates room for differentiated excipient systems, but any reformulation must preserve solubility, chemical stability, rapid dilution, intravenous tolerability, and compatibility with chemotherapy workflows.

What is fosaprepitant and why do excipients matter?

Fosaprepitant dimeglumine is a water-soluble phosphorylated prodrug of aprepitant. After intravenous administration, it is rapidly converted to aprepitant, which blocks the neurokinin-1 receptor and suppresses substance P-mediated emesis.[1]

Fosaprepitant presents several formulation challenges:

• The active pharmaceutical ingredient has a high ionic and molecular burden.
• The product must remain stable during reconstitution and dilution.
• Intravenous administration requires control of particulate matter, osmolality, pH, and extractables.
• Chemotherapy patients may be exposed to multiple infusion products in one treatment visit.
• Polysorbate 80 can create concerns involving hypersensitivity, oxidation, peroxide formation, and container interaction.
• The product must be compatible with common infusion diluents and administration sets.

Excipient selection therefore affects more than manufacturability. It influences nursing time, pharmacy preparation, adverse-event perception, product differentiation, and hospital purchasing.

What excipients are used in the Emend fosaprepitant formulation?

The reference fosaprepitant injection uses a lyophilized powder containing fosaprepitant dimeglumine, polysorbate 80, lactose anhydrous, and pH-adjusting agents.[1] The vial is reconstituted and diluted before intravenous administration.

Reference formulation profile

Attribute	Emend for Injection
Active ingredient	Fosaprepitant dimeglumine
Prodrug	Fosaprepitant
Active metabolite	Aprepitant
Dosage form	Lyophilized intravenous powder
Primary surfactant	Polysorbate 80
Bulking or stabilizing excipient	Lactose anhydrous
pH control	Hydrochloric acid and sodium hydroxide
Administration	Intravenous infusion after reconstitution and dilution
Main clinical use	Prevention of acute and delayed chemotherapy-induced nausea and vomiting
FDA reference product	Emend for Injection

Polysorbate 80 improves wetting and helps maintain the active ingredient in solution after reconstitution. Lactose contributes bulk and can support cake structure in a lyophilized product. The formulation must balance surfactant concentration against infusion tolerability and degradation risk.

The precise quantitative composition should be taken from the applicable FDA-approved prescribing information and product-specific chemistry, manufacturing, and controls documentation. Formulation composition may differ by strength and manufacturer.

What excipient risks affect fosaprepitant commercial performance?

The principal excipient risks are polysorbate degradation, infusion reactions, reconstitution complexity, and compatibility limits.

Polysorbate 80 degradation

Polysorbate 80 can undergo hydrolysis and oxidation. Degradation may generate free fatty acids, peroxides, and subvisible particles. These products can affect appearance, stability, protein formulations administered in the same clinical setting, and intravenous tolerability.

For fosaprepitant, the risk is managed through:

• Low-peroxide excipient specifications
• Controlled oxygen exposure
• Appropriate vial and stopper selection
• Light protection where required
• Stability-indicating analytical methods
• Control of metal ions and other oxidation catalysts
• Defined hold times after reconstitution and dilution

A polysorbate-free formulation could create a commercial advantage if it provides equal or better stability without introducing another tolerability or manufacturing problem.

Infusion-related hypersensitivity

The Emend label warns about serious hypersensitivity reactions, including anaphylaxis, during or soon after infusion.[1] The active ingredient, excipients, administration rate, and patient-specific factors can all affect clinical interpretation of these events.

Excipient strategies cannot claim elimination of hypersensitivity risk without clinical evidence. They can, however, target known formulation concerns through:

• Surfactant substitution
• Lower surfactant loading
• Alternative pH and buffer systems
• Reduced infusion volume
• Improved dilution instructions
• More predictable post-reconstitution stability

Reconstitution and pharmacy labor

A lyophilized vial requires reconstitution, dilution, inspection, labeling, and administration. Every additional preparation step creates labor cost and opportunities for handling error.

A ready-to-use liquid or concentrated solution could compete on total treatment cost even if its acquisition price is higher. The relevant economic calculation includes pharmacy technician time, clean-room utilization, consumables, wastage, and chair or infusion-suite throughput.

What formulation technologies could improve fosaprepitant?

The most commercially credible approaches are incremental reformulations that preserve the existing intravenous route and clinical use.

Polysorbate-free aqueous solution

A polysorbate-free aqueous formulation would be the clearest excipient-led differentiation strategy. Potential solubilization systems include:

• Cyclodextrin derivatives
• Nonionic surfactants other than polysorbate 80
• Phospholipid-based solubilizers
• Amino-acid or polyol stabilization systems
• pH-controlled salt systems
• Mixed-solvent systems compatible with intravenous use

The formulation must avoid excessive osmolality, hemolysis, precipitation after dilution, and unacceptable injection-site reactions. A new excipient system also creates a regulatory burden because the sponsor must establish toxicological and clinical acceptability for the complete formulation.

Ready-to-use liquid

A ready-to-use product could remove reconstitution and reduce preparation time. Its main technical barriers are:

• Long-term chemical stability in solution
• Control of hydrolysis and oxidation
• Container closure compatibility
• Prevention of precipitation at refrigerated and room temperatures
• Acceptable shelf life
• Compatibility with standard infusion diluents

A ready-to-use presentation could be supplied in a vial, prefilled syringe, or infusion bag. The vial is the most conservative option. A prefilled syringe would require a stronger compatibility package and a clear administration workflow.

Concentrated liquid for dilution

A concentrated presentation could reduce vial size and shipping volume while preserving pharmacy dilution practices. This approach may be attractive for high-throughput oncology centers, but it must provide a sufficiently wide dilution margin.

Important development parameters include:

• Minimum and maximum dilution volumes
• Compatible diluents
• Stability after dilution
• Line and bag compatibility
• Maximum permitted hold time
• Particulate and extractables control
• Administration rate

Alternative lyophilized cake

A reformulated lyophilized product can retain the operational familiarity of Emend while improving reconstitution time, cake integrity, or storage stability. Possible changes include:

• Alternative bulking agents
• Modified sugar systems
• Improved surfactant grade
• Different pH-adjustment strategy
• Lower residual moisture
• Enhanced stopper and vial configuration

This strategy has lower technical risk than a liquid product but offers less differentiation unless it reduces preparation time or improves shelf life.

Nanoparticle or emulsion systems

Nanoemulsions and lipid systems could improve solubilization, but they may be commercially unnecessary because fosaprepitant is already designed as a water-soluble prodrug. These systems would add manufacturing complexity, characterization requirements, and potential safety questions.

Cinvanti, an injectable aprepitant emulsion, demonstrates that emulsion technology is commercially viable in the NK1 antagonist class. Its excipient system includes soybean oil, egg lecithin, oleic acid, sodium oleate, and other formulation components.[2] A fosaprepitant emulsion would need to show a meaningful advantage over both the reference fosaprepitant product and the established aprepitant emulsion.

How does fosaprepitant compare with injectable aprepitant?

Fosaprepitant and aprepitant injectable products compete within the same antiemetic treatment pathway but use different formulation strategies.

Attribute	Fosaprepitant injection	Aprepitant injectable emulsion
Active administered	Fosaprepitant prodrug	Aprepitant
Delivery system	Lyophilized or solution-based IV product	Lipid emulsion
Key formulation issue	Surfactant use, reconstitution, solution stability	Emulsion stability, lipid excipients, container compatibility
Reference products	Emend for Injection	Cinvanti
Commercial differentiation	Ready-to-use, polysorbate-free, lower preparation burden	Alternative excipient profile and liquid administration
Generic pathway	Abbreviated application based on reference product	Product-specific injectable emulsion requirements
Hospital advantage	Familiar prodrug platform and established workflow	Ready-to-use liquid formulation

The two products are not automatically substitutable from a formulation or regulatory perspective. A generic fosaprepitant product generally must match the reference product’s critical quality attributes and demonstrate pharmaceutical equivalence under the applicable FDA pathway. A new delivery system may require a different regulatory strategy.

What commercial opportunities exist for fosaprepitant excipients?

1. Polysorbate-free product

A polysorbate-free fosaprepitant product could target institutions concerned with excipient tolerability, peroxide control, or surfactant-related particles. The value proposition would depend on demonstrated clinical and stability benefits, not on the absence of polysorbate alone.

2. Ready-to-administer oncology product

An infusion-ready product could reduce pharmacy labor and preparation steps. Hospitals may accept a premium where the product:

• Arrives in a standard administration container
• Requires no aseptic reconstitution
• Has a defined room-temperature hold time
• Fits existing barcode and medication-administration systems
• Reduces dose preparation waste

3. Smaller-volume presentation

A lower-volume formulation could benefit outpatient infusion centers with high patient throughput. A smaller container also lowers shipping and storage requirements.

4. Extended post-dilution stability

A formulation with a longer validated hold time could improve batch preparation and reduce discarded doses. This opportunity is particularly relevant where treatment schedules create variable demand.

5. Pediatric and weight-based dosing

The approved use of fosaprepitant is centered on chemotherapy-related nausea and vomiting. Pediatric oncology may offer a formulation opportunity if dosing flexibility, lower administration volume, or preservative-free packaging addresses a recognized clinical need.

6. Global-market formulation

A formulation designed for markets with constrained cold-chain infrastructure could compete through room-temperature stability, simplified packaging, and lower preparation requirements. Geographic development should account for local excipient restrictions, container standards, and pharmacopoeial requirements.

7. Excipient supply and dual sourcing

Manufacturers can create value through qualified sources of low-peroxide polysorbate 80, pharmaceutical-grade lactose, specialized cyclodextrins, and alternative injectable surfactants. Supply continuity is a commercial differentiator for oncology injectables because manufacturing interruptions can affect hospital treatment schedules.

What patents protect fosaprepitant formulation opportunities?

Core fosaprepitant and aprepitant composition-of-matter rights are mature relative to the marketed products. Commercial protection for a new product is more likely to depend on formulation, dosage form, manufacturing process, packaging, stability, and method-of-use claims than on a new basic compound claim.

Potential patent claim categories include:

• Fosaprepitant formulations using alternative surfactants
• Polysorbate-free aqueous solutions
• Specific pH and osmolality ranges
• Lyophilized cakes with defined residual moisture
• Ready-to-use infusion formulations
• Container closure systems
• Reconstitution and dilution methods
• Extended stability after dilution
• Combination administration with chemotherapy regimens
• Pediatric dosing or specific patient populations
• Manufacturing processes that control particles or degradation products

A sponsor should separate patent value from regulatory exclusivity. A formulation patent may provide litigation leverage, but it does not necessarily prevent approval of a generic that uses a different excipient system. Conversely, a narrow formulation patent may have limited practical value if competitors can design around the claimed excipient concentration or dosage form.

When does fosaprepitant lose exclusivity?

The principal Emend injection exclusivity period has passed, and generic fosaprepitant products have entered the U.S. market. The commercial question is therefore no longer whether the reference product has basic market exclusivity. It is whether a differentiated formulation can establish new patent or regulatory protection.

U.S. regulatory status

Emend for Injection was approved by the FDA for prevention of acute and delayed nausea and vomiting associated with highly emetogenic and moderately emetogenic chemotherapy.[1] Generic fosaprepitant dimeglumine injections are approved through abbreviated applications and compete primarily on price, supply reliability, and contract access.

Orange Book status

The FDA Orange Book is the controlling source for current listed patents, exclusivity codes, and therapeutic-equivalence information. Fosaprepitant injectable products should be assessed by National Drug Code, strength, dosage form, and reference-listed-drug relationship. Product-specific Orange Book entries should be reviewed before making a Paragraph IV, launch, or settlement assessment.[3]

Paragraph IV and generic entry risk

Because generic injectable fosaprepitant products are already commercially established, future entry risk is highest for:

• Additional generic manufacturers
• Contract-manufactured hospital products
• Private-label injectable suppliers
• Formulations that avoid the reference product’s excipient claims
• Products using alternative vial or liquid presentations

For a new formulation, Paragraph IV risk depends on the claims listed for the reference or innovator product and on whether the new formulation is itself protected by enforceable patents. A formulation patent with narrow concentration limits is more vulnerable to design-around than a patent covering a broad delivery platform.

What patent litigation and settlement issues affect fosaprepitant?

The highest-value disputes would involve formulation patents, manufacturing processes, and abbreviated-application certifications. Litigation risk is lower for expired core compound rights and higher for newly developed commercial presentations.

Key litigation questions include:

1. Whether the asserted claims cover the generic’s actual excipient system.
2. Whether the claims are invalid for lack of novelty or obviousness.
3. Whether the generic can avoid infringement through a different surfactant, pH range, or container.
4. Whether the patent is listed in the Orange Book.
5. Whether a settlement contains a delayed-entry date, authorized-generic provision, or supply arrangement.
6. Whether the product is subject to a 30-month stay under the Hatch-Waxman framework.

No single patent number should be treated as controlling without matching the claim scope to the marketed strength, dosage form, and formulation. Settlement economics would be driven by the remaining patent term, generic-at-risk exposure, expected injectable price erosion, and the availability of alternative NK1 antagonist products.

How strong is the fosaprepitant patent estate?

The legacy estate is commercially weaker than an active composition-of-matter portfolio because the product has faced generic competition. A new formulation estate could be strong if it has:

• Broad claims covering a commercially necessary excipient combination
• Multiple independent claim types
• Experimental data showing unexpected stability or tolerability
• Claims that cover both vial and ready-to-use formats
• Manufacturing and packaging claims that are difficult to design around
• Patent term extending well beyond launch
• Regulatory exclusivity or clinical data protection supporting the product

The estate is weaker if it relies on a single narrow excipient ratio, an obvious substitution, or a process claim that competitors can avoid through standard manufacturing changes.

What regulatory barriers affect new fosaprepitant formulations?

The regulatory pathway depends on how closely the product follows the approved reference.

Generic-equivalent strategy

A sponsor seeking an abbreviated approval generally benefits from matching the reference formulation and dosage form. Major excipient changes can create questions about pharmaceutical equivalence, safety, local tolerance, and product performance.

505(b)(2) strategy

A materially different formulation, such as a ready-to-use liquid or alternative delivery system, may be more suitable for a 505(b)(2) application. The sponsor could rely partly on existing fosaprepitant or aprepitant data while generating bridging data for the new formulation.

Critical studies may include:

• Comparative pharmacokinetics
• In vitro release or dilution studies
• Local tolerance
• Infusion reaction monitoring
• Compatibility and extractables testing
• Stability under intended storage and administration conditions
• Clinical bridging where formulation changes affect exposure or safety

Biosimilar risk

Biosimilar competition is not relevant to fosaprepitant because fosaprepitant is a small-molecule drug, not a biologic. The relevant competitive threats are generic injectable fosaprepitant, injectable aprepitant, oral aprepitant, fixed-dose antiemetic combinations, and competing NK1 antagonists.

What revenue exposure and competitive factors matter?

Fosaprepitant revenue is exposed to generic price compression and hospital tendering. The highest-value accounts are oncology hospitals, integrated delivery networks, outpatient infusion centers, and specialty distributors.

Commercial performance depends on:

• Contract price
• Backorder frequency
• Vial utilization and waste
• Pharmacy preparation labor
• Shelf life
• Administration time
• Formulary positioning
• Availability of Cinvanti and other NK1 alternatives
• Use of oral aprepitant and combination regimens
• Chemotherapy treatment volume

An excipient-led product should be priced against total cost of care, not only acquisition price. A ready-to-use product may justify a premium if it reduces pharmacy labor and wastage. A polysorbate-free product may command value in selected institutions, but broad adoption requires clear operational or clinical evidence.

What generic launch scenarios exist for fosaprepitant?

Scenario	Commercial effect	Main barrier
Additional low-price generic	Rapid price erosion	Manufacturing economics
Reliable shortage-resistant supplier	Share gain despite modest premium	Supply scale
Polysorbate-free formulation	Premium niche or formulary differentiation	Clinical and regulatory evidence
Ready-to-use liquid	Lower pharmacy labor and preparation time	Solution stability
Concentrated formulation	Lower logistics cost	Dilution compatibility
Alternative emulsion	Direct competition with aprepitant emulsion	Complex manufacturing
Pediatric or specialty presentation	Segment-specific pricing	Limited market size

The most realistic near-term opportunity is a differentiated formulation with a clear pharmacy workflow benefit. A novel excipient system without measurable operational value is unlikely to overcome generic pricing pressure.

Key Takeaways

• Fosaprepitant is an established intravenous prodrug of aprepitant with mature core intellectual property.
• The reference product uses polysorbate 80 and lactose in a lyophilized formulation.
• The strongest excipient opportunities involve polysorbate reduction or elimination, ready-to-use liquid products, improved post-dilution stability, and lower preparation burden.
• Generic competition limits the value of undifferentiated fosaprepitant products.
• New formulation patents should cover excipients, dosage form, process, packaging, and stability rather than rely on one narrow composition claim.
• A 505(b)(2) pathway may be appropriate for materially different liquid or delivery systems.
• Biosimilar risk does not apply. Generic and alternative injectable NK1 antagonist competition does.
• Commercial success will depend on hospital economics, supply reliability, pharmacy labor, and formulary access.

FAQs About Fosaprepitant Excipient Commercialization

Can polysorbate 80 be removed from fosaprepitant?

Yes, but removal requires a replacement solubilization and stabilization system that maintains intravenous safety, solution clarity, chemical stability, and dilution compatibility. The replacement excipient may create its own regulatory and toxicological requirements.

Is lactose essential in fosaprepitant lyophilized products?

No. Lactose is used in the reference formulation, but other bulking or stabilizing systems may be technically possible. Any substitution must preserve cake structure, residual moisture control, reconstitution performance, and product stability.

Could fosaprepitant be sold as a prefilled syringe?

Potentially. A prefilled syringe would require evidence addressing syringe material compatibility, extractables and leachables, stability, dose accuracy, particulate control, and administration workflow. The commercial opportunity is strongest where it eliminates pharmacy compounding steps.

Does a new fosaprepitant formulation qualify for separate patent protection?

It can qualify if the formulation, process, packaging, or use is novel and nonobvious. The most defensible claims generally combine a defined excipient system with demonstrated stability, tolerability, or operational advantages.

Is Cinvanti a direct generic substitute for fosaprepitant?

No. Cinvanti contains aprepitant in an injectable emulsion, while fosaprepitant products administer the phosphorylated prodrug. Product substitution depends on FDA labeling, clinical protocol, formulary policy, and institutional pharmacy procedures.

References

1. U.S. Food and Drug Administration. (2024). Emend for injection: Prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Food and Drug Administration. (2024). Cinvanti: Prescribing information. Heron Therapeutics, Inc.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda.